These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 11260416

  • 1. Plasminogen activator inhibitor-1 gene polymorphism 4G/4G genotype and lupus nephritis in Chinese patients.
    Wang AY, Poon P, Lai FM, Yu L, Choi PC, Lui SF, Li PK.
    Kidney Int; 2001 Apr; 59(4):1520-8. PubMed ID: 11260416
    [Abstract] [Full Text] [Related]

  • 2. 4G/5G plasminogen activator inhibitor-1 and -308 A/G tumor necrosis factor-α promoter gene polymorphisms in Argentinean lupus patients: focus on lupus nephritis.
    Muñoz SA, Aranda F, Allievi A, Orden AO, Perés Wingeyer S, Trobo R, Alvarez A, Eimon A, Barreira JC, Schneeberger E, Dal Pra F, Sarano J, Hofman J, Chamorro J, de Larrañaga G.
    Clin Exp Med; 2014 Feb; 14(1):83-9. PubMed ID: 23143392
    [Abstract] [Full Text] [Related]

  • 3. Association between the PAI-1 4G/5G Gene Polymorphism and the Risk of Systemic Lupus Erythematosus/Lupus Nephritis.
    Li W, Mao S, Wu L, Shi W, Zhang J, Wang Z.
    Crit Rev Eukaryot Gene Expr; 2019 Feb; 29(1):85-94. PubMed ID: 31002598
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The influence of 4G/5G polymorphism in the plasminogen-activator-inhibitor-1 promoter on COVID-19 severity and endothelial dysfunction.
    Yatsenko T, Rios R, Nogueira T, Salama Y, Takahashi S, Adachi E, Tabe Y, Hattori N, Osada T, Naito T, Takahashi K, Hattori K, Heissig B.
    Front Immunol; 2024 Feb; 15():1445294. PubMed ID: 39281671
    [Abstract] [Full Text] [Related]

  • 7. Plasminogen activator inhibitor-1 4G/5G polymorphism and efficacy of reperfusion therapy in acute myocardial infarction.
    Sibbing D, von Beckerath O, von Beckerath N, Koch W, Mehilli J, Schwaiger M, Schömig A, Kastrati A.
    Blood Coagul Fibrinolysis; 2005 Oct; 16(7):511-5. PubMed ID: 16175011
    [Abstract] [Full Text] [Related]

  • 8. Investigation of association between plasminogen activator inhibitor type-1 (PAI-1) gene 4G/5G polymorphism frequency and plasma PAI-1 enzyme activity in patients with acute stroke.
    Kucukarabaci B, Gunes HV, Ozdemir G, Cosan D, Ozbabalik D, Dikmen M, Degirmenci I.
    Genet Test; 2008 Sep; 12(3):443-51. PubMed ID: 18662099
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Epistatic effect of plasminogen activator inhibitor 1 and beta-fibrinogen genes on risk of glomerular microthrombosis in lupus nephritis: interaction with environmental/clinical factors.
    Gong R, Liu Z, Li L.
    Arthritis Rheum; 2007 May; 56(5):1608-17. PubMed ID: 17469143
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Plasminogen activator inhibitor-1 4G/5G gene polymorphism in patients with myocardial or cerebrovascular infarction in Tianjin, China.
    Zhan M, Zhou Y, Han Z.
    Chin Med J (Engl); 2003 Nov; 116(11):1707-10. PubMed ID: 14642142
    [Abstract] [Full Text] [Related]

  • 14. The -675 4G/5G PAI-1 polymorphism confers genetic susceptibility to systemic lupus erythematosus, its clinical manifestations, and comorbidities in Mexican-Mestizo population.
    Anaya-Macias BU, De la Cruz-Mosso U, Palafox-Sánchez CA, Parra-Rojas I, Martínez-Bonilla G, González-López L, Gámez-Nava JI, Pérez-Guerrero EE, Barrientos-Avalos SL, Muñoz-Valle JF.
    Autoimmunity; 2020 Mar; 53(2):71-77. PubMed ID: 31829037
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis.
    Sartori MT, Wiman B, Vettore S, Dazzi F, Girolami A, Patrassi GM.
    Thromb Haemost; 1998 Dec; 80(6):956-60. PubMed ID: 9869167
    [Abstract] [Full Text] [Related]

  • 17. Association between plasminogen activator inhibitor‑1 (PAI-1) 4G/5G polymorphism and circulating PAI-1 level in systemic lupus erythematosus and rheumatoid arthritis : A meta-analysis.
    Bae SC, Lee YH.
    Z Rheumatol; 2020 Apr; 79(3):312-318. PubMed ID: 31428858
    [Abstract] [Full Text] [Related]

  • 18. Association of Plasminogen Activator Inhibitor 1 (PAI-1) 4G/5G Polymorphism and Susceptibility to SLE in Egyptian Children and Adolescents: A Multicenter Study.
    Yousef AA, Mohamed FY, Boraey NF, Akeel NE, Soliman AA, Waked NM, Hashem MIA, Shehata H, Fahmy DS, Ismael A, Ibrahim LM, Ibrahim MAM, Salem HF, Yousry SM, Osman SF, Fouad RA, Enan ET, Attia MA, Afify MR, Zeidan NMS, Nashat M.
    J Inflamm Res; 2020 Apr; 13():1103-1111. PubMed ID: 33363394
    [Abstract] [Full Text] [Related]

  • 19. [Association of plasminogen activator inhibitor-1 gene 4G/5G polymorphism and coronary heart disease in Chinese patients].
    Guan L, Ji X, Wang J, Zhang A, Zhang Y, Zhao L.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Oct; 19(5):393-6. PubMed ID: 12362314
    [Abstract] [Full Text] [Related]

  • 20. The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels.
    Diamanti-Kandarakis E, Palioniko G, Alexandraki K, Bergiele A, Koutsouba T, Bartzis M.
    Eur J Endocrinol; 2004 Jun; 150(6):793-8. PubMed ID: 15191349
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.